Few industries in the medical device sector have been as hard-hit in recent years as the cardiac rhythm management, or CRM, business. One look around the industry tells it all. Medtronic's (NYSE: MDT ) cardiac rhythm disease management business lost 2% of its sales year over year in its most recent fiscal year, led by its lagging defibrillator business. Boston Scientific (NYSE: BSX ) followed closely in its larger rival's footsteps, as its own implantable cardioverter defibrillator products, or ICDs, saw sales fall nearly 4% in the most recent quarter.
Yet no company's as at risk to the CRM market's downturn as St. Jude Medical (NYSE: STJ ) . St. Jude's even more reliant on defibrillators for its revenue than either Boston Scientific or Medtronic, as the company pulls in more than 30% of its total sales from the products. The business' downturn has taken a toll on St. Jude's finances even as this surging stock has soared in 2013.
Finally, however, hope is rising for the future. St. Jude released its third-quarter earnings Wednesday, and the results from its defibrillator business at long last showed growth. Can this result turn around St. Jude's fortunes? In the video below, Motley Fool contributor Dan Carroll tells you what you need to know about St. Jude's most important segment and whether the CRM industry can continue these gains as Medtronic and Boston Scientific report earnings in the coming weeks.
How to make the most of your financial future
St. Jude's stock has surged this year despite the company's struggles, but many investors have missed out on the best of the market's gains. Millions of Americans have waited on the sidelines since the market meltdown in 2008 and 2009, too scared to invest and put their money at further risk. Yet those who've stayed out of the market have missed out on huge gains and put their financial futures in jeopardy. In our brand-new special report, "Your Essential Guide to Start Investing Today," The Motley Fool's personal finance experts show you why investing is so important and what you need to do to get started. Click here to get your copy today -- it's absolutely free.